Cholangiocarcinoma

Michela Squadroni, Luca Tondulli, Gemma Gatta, Stefania Mosconi, Giordano Beretta, Roberto Labianca

Research output: Contribution to journalReview articlepeer-review

Abstract

Biliary tract cancer accounts for <1% of all cancers and affects chiefly an elderly population, with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and distal) and gallbladder cancer, with different pathogenesis and prognosis. The treatment is based on surgery (whenever possible), radiotherapy in selected cases, and chemotherapy. The standard cytotoxic treatment for advanced/metastatic disease is represented by the combination of gemcitabine and cisplatin, whereas fluoropyrimidines are generally administered in second line setting. At the present time, no biologic drug demonstrated a clear efficacy in this cancer, although the molecular characterisation could provide a promising basis for experimental treatments. A good supportive care and an early palliative care are warranted in most patients and should be delivered as a part of a global approach.

Original languageEnglish
Pages (from-to)11-31
Number of pages21
JournalCritical Reviews in Oncology/Hematology
Volume116
DOIs
Publication statusPublished - Aug 1 2017

Keywords

  • Biliary tract
  • cancer
  • diagnosis
  • incidence
  • multidisciplinary treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this